Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by United Capital Financial Advisers LLC

Posted by Defense World Staff on Mar 8th, 2023

United Capital Financial Advisers LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 48.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,995 shares of the biopharmaceutical company’s stock after selling 8,473 shares during the quarter. United Capital Financial Advisers LLC’s holdings in Halozyme Therapeutics were worth $356,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Meeder Asset Management Inc. grew its position in shares of Halozyme Therapeutics by 223.6% in the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 512 shares during the last quarter. Brown Brothers Harriman & Co. acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $35,000. IFP Advisors Inc grew its position in shares of Halozyme Therapeutics by 87.9% in the third quarter. IFP Advisors Inc now owns 1,717 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 803 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $40,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $57,000. 96.32% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $47.71, for a total value of $477,100.00. Following the completion of the sale, the director now owns 39,045 shares of the company’s stock, valued at $1,862,836.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $47.71, for a total value of $477,100.00. Following the completion of the sale, the director now owns 39,045 shares of the company’s stock, valued at $1,862,836.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 2,525 shares of the stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $49.26, for a total transaction of $124,381.50. Following the completion of the sale, the chief financial officer now directly owns 9,066 shares of the company’s stock, valued at approximately $446,591.16. The disclosure for this sale can be found here. Insiders have sold a total of 93,586 shares of company stock valued at $4,828,446 over the last quarter. Company insiders own 2.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HALO shares. Benchmark upped their price objective on shares of Halozyme Therapeutics from $55.00 to $68.00 and gave the company a “buy” rating in a research note on Thursday, December 8th. SVB Leerink reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating on the stock in a research note on Wednesday, January 11th. JPMorgan Chase & Co. reduced their price objective on shares of Halozyme Therapeutics from $54.00 to $52.00 and set an “overweight” rating on the stock in a research note on Thursday, February 23rd. JMP Securities reissued a “market outperform” rating and set a $66.00 price objective (up previously from $62.00) on shares of Halozyme Therapeutics in a research note on Wednesday, February 22nd. Finally, Wells Fargo & Company started coverage on shares of Halozyme Therapeutics in a research note on Monday, November 28th. They set an “overweight” rating and a $65.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $43.40 on Wednesday. The company has a quick ratio of 4.88, a current ratio of 5.65 and a debt-to-equity ratio of 8.79. The company has a market cap of $5.87 billion, a P/E ratio of 29.93, a P/E/G ratio of 0.60 and a beta of 1.26. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.92 and a fifty-two week high of $59.46. The firm’s 50 day moving average is $51.45 and its two-hundred day moving average is $48.86.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.